Howard D. Homesley

Howard D. Homesley's AcademicInfluence.com Rankings

Howard D. Homesley

Philosophy

#9940

World Rank

#13572

Historical Rank

Logic

#6892

World Rank

#8450

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Howard D. Homesley's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Howard D. Homesley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Howard D. Homesley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Incorporation of bevacizumab in the primary treatment of ovarian cancer. (2011) (1942)
Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study (1987) (1810)
Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study (1991) (931)
Surgical Pathologic Spread Patterns of Endometrial Cancer (2006) (703)
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. (1994) (687)
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. (1991) (468)
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. (1999) (439)
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. (1996) (428)
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. (1998) (396)
Radiation Therapy Versus Pelvic Node Resection for Carcinoma of the Vulva With Positive Groin Nodes (1986) (373)
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. (2004) (347)
Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). (1991) (308)
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study (1986) (277)
Cis‐platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group (1981) (270)
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. (2008) (255)
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. (2019) (232)
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. (2009) (212)
Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. (1999) (212)
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. (1995) (205)
Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) (1993) (204)
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. (2007) (201)
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. (2010) (194)
Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin Versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group) (1985) (185)
Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. (2001) (174)
A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. (2011) (164)
Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. (1990) (159)
Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assay (1985) (152)
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. (1991) (145)
Positive groin lymph nodes in superficial squamous cell vulvar cancer. A Gynecologic Oncology Group Study. (1987) (140)
Radiation Therapy Compared With Pelvic Node Resection for Node-Positive Vulvar Cancer: A Randomized Controlled Trial (2009) (133)
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. (1996) (131)
Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. (1992) (129)
Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group study (1989) (123)
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. (1989) (116)
Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. (1989) (112)
Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. (1992) (109)
Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. (2005) (102)
Determinants of Survival of Surgically Staged Patients With Endometrial Carcinoma Histologically Confined to the Uterus: Implications for Therapy (1992) (98)
Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. (1991) (97)
Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. (2006) (89)
Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. (1998) (86)
Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments. (1980) (82)
A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. (2001) (77)
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. (1995) (76)
Phase II trial of cisplatin as second‐line chemotherapy in patients with advanced or recurrent endometrial carcinoma A Gynecologic Oncology Group study (1984) (74)
Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. (2004) (73)
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. (2014) (70)
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. (2013) (69)
cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. (1979) (69)
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. (1999) (69)
Reassessment of the surgical scrub. (1978) (67)
Positive groin lymph nodes in superficial squamous cell vulvar cancer (1987) (65)
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. (2015) (64)
Intravenous vincristine infusion: Phase I trial (1981) (60)
Multidrug Treatment of Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study (1984) (58)
Phase II trial of cisplatin as first‐line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study (1989) (52)
Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. (1992) (52)
Management of vulvar cancer (1995) (51)
Stage II Endometrial Adenocarcinoma: Memorial Hospital for Cancer, 1949-1965 (1977) (50)
A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. (1994) (50)
Relationship of lesion size to survival in patients with stage IB squamous cell carcinoma of the cervix uteri treated by radiation therapy. (1980) (48)
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. (2006) (45)
Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. (1993) (43)
Intralesional interferon alfa-2b for the treatment of genital warts. (1990) (43)
A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. (1996) (43)
Adriamycin Chemotherapy for Malignant Mixed Mesodermal Tumor of the Ovary A Gynecologic Oncology Group Study (1986) (42)
Circadian-timed Combination Doxorubicin-cisplatin Chemotherapy for Advanced Endometrial Carcinoma: A Phase Ii Study of the Gynecologic Oncology Group (1993) (42)
Cisplatin-associated cortical blindness. (1981) (42)
Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. (1990) (41)
Endometrial cancer: prognostic factors. (1994) (40)
Autoimmune hemolytic anemia and ovarian dermoid cysts: Case report and review of the literature (1981) (40)
Feasibility of laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a gynecologic oncology group study (2003) (40)
Phase II study of Ifosfamide and Mesna in refractory adenocarcinoma of the endometrium (1994) (40)
Prognostic Factors in Surgical Stage III and IV Carcinoma of the Endometrium (1994) (40)
A Phase II Study of the Efficacy of Recombinant Interferon Gamma in Relapsing Ovarian Adenocarcinoma (1988) (36)
Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. (1984) (35)
Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium (1986) (35)
Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study (2005) (34)
Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study. (2018) (34)
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. (2006) (34)
Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. (1986) (34)
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. (1995) (32)
Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. (1998) (32)
Gynecologic Oncology Group experience with ifosfamide. (1990) (32)
Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. (2010) (31)
Antiestrogenic Potency of Toremifene and Tamoxifen in Postmenopausal Women (1993) (30)
Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response (2012) (28)
Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ‐cell tumors. A trial of the Gynecologic Oncology Group (1990) (28)
Analysis of the relationships of the ploidy and cell cycle kinetics to differentiation and the female sex steroid hormone receptors in adenocarcinoma of the endometrium. (1986) (27)
Cancers of the uterine cervix and endometrium: major issues and future research directions. (1994) (26)
Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study. (1986) (26)
Cis‐platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: A phase II study of the Gynecologic Oncology Group (1983) (25)
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. (1989) (25)
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. (2011) (25)
In vitro chemotherapy testing of gynecologic tumors: basis for planning therapy? (1983) (24)
Randomized Comparison of Cisplatin plus Epirubicin or Doxorubicin for Advanced Epithelial Ovarian Carcinoma: A Multicenter Trial (1992) (24)
Development of single-agent chemotherapy regimens for gestational trophoblastic disease. (1994) (23)
Is Hysterectomy a Risk Factor for Vaginal Cancer (1986) (23)
Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus corynebacterium parvum (a gynecologic oncology group study) (1986) (21)
Umbilical metastasis from gynecologic malignancies: a primary carcinoma of the fallopian tube. (1981) (20)
A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. (2016) (20)
Identification of Antigenic Components Recognized by “Membrane‐Bound” Antibodies From Ovarian Cancer Patients (1984) (20)
Total hip arthroplasty revision: a decade of change. (2004) (20)
A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer (2008) (19)
Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: cisplatin followed by radiation therapy--a pilot study of the Gynecologic Oncology Group. (1987) (19)
Ovarian germ cell tumors: Adjuvant trials of the Gynecologic Oncology Group (GOG) (1989) (19)
A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients. (2002) (18)
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. (2012) (18)
Results of revision total knee arthroplasty after exposure of the knee with extensor mechanism tenolysis. (2004) (18)
Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide. (1985) (18)
Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group Study). (1989) (18)
Management of endometrial cancer. (1996) (17)
Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma: A Gynecologic Oncology Group study (1985) (17)
Lymph node findings and outcome in squamous cell carcinoma of the vulva (1994) (17)
Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study. (1996) (17)
Revised 1988 International Federation of Gynecology and Obstetrics Staging Systems for Endometrial and Vulvar Cancer: An Assessment (1992) (16)
Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. (2010) (16)
Vincristine infusion in refractory gynecologic malignancies. (1986) (16)
Serological response patterns to herpes virus type 2 early and late antigens in cervical carcinoma patients. (1979) (15)
A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. (1996) (15)
A Phase II Trial of Gallium Nitrate (NSC #15200) in Nonsquamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study (1995) (14)
Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group (1988) (13)
Comparison of Cryosurgery and Carbon Dioxide Laser Ablation for Treatment of Cervical Intraepithelial Neoplasia (1985) (13)
Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group (1998) (12)
Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. (1984) (12)
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study. (1989) (12)
Placental‐Type Alkaline Phosphatase in Ovarian Cancer Fluids and Tissues (1984) (11)
Gynecologic Oncology Group studies with ifosfamide. (1992) (11)
Present status and future direction of clinical trials in advanced endometrial carcinoma. (2008) (11)
Early Invasive Carcinoma of the Cervix (3− to 5-mm Invasion): Risk Factors and Prognosis (1998) (11)
Hazards of central venous pressure monitoring: pericardial tamponade. (1971) (11)
Chemotherapy of advanced squamous carcinoma of the cervix: A phase I‐II study of high‐dose cisplatin and cyclophosphamide A pilot study of the Gynecologic Oncology Group (1984) (10)
Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study (2011) (10)
Combined interferon alf a and doxorubicin in the treatment of advanced cervical cancer (1991) (10)
Radiation-induced vesicosacral fistula: treatment with continent urinary diversion. (1995) (9)
Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. (1996) (9)
ICRF‐159 (Razoxane) in Patients with Advanced Adenocarcinoma of the Endometrium A Gynecologic Oncology Group Study (1986) (9)
Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. (2005) (9)
Recurrence in endometrial carcinoma as a function of extended surgical staging data (1984) (9)
Phase I trials of high-dose cytosine arabinoside (HDara-C) and HDara-C plus cisplatin in patients with advanced malignancies. (1985) (9)
Phase II Trial of Piperazinedione in the Treatment of Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study (1986) (9)
Single dose carbenicillin versus T-tube drainage in patients undergoing vaginal hysterectomy. (1981) (9)
Use of the Human Tumor Stem Cell Assay to Study Chemotherapy Sensitivity in Cancer of the Cervix (1984) (9)
Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms. I. Quantitation of antibodies. (1985) (9)
Localized ovarian cancer in the elderly: The gynecologic oncology group experience (2010) (9)
A phase I trial of recombinant leukocyte alpha 2 interferon in patients with advanced malignancy. (1985) (8)
Cisplatin, Vinblastine, and Bleomycin in Advanced and Recurrent Ovarian Germ-Cell Tumors: A Trial of the Gynecologic Oncology Group (1990) (8)
Use of colposcopically directed, four-quadrant cervical biopsy by the colposcopy trainee. (1984) (8)
Embryonal Rhabdomyosarcoma: Adjuvant and Ex Vivo Assay-Directed Chemotherapy (2009) (7)
Hazards of central venous pressure monitoring: pericardial tamponade. (1972) (7)
Rapid escalation of weekly intramuscular methotrexate for nommetastatic gestational trophoblastic disease: A gynecologic oncology group study (1991) (7)
Aminothiadiazole (NSC #4728) in Patients With Advanced Cervical Carcinoma A Phase II Study of the Gynecologic Oncology Group (1987) (7)
The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. (2019) (7)
CISPLATIN IN THE TREATMENT OF ADVANCED OR RECURRENT CERVIX AND UTERINE CANCER (1980) (7)
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. (1996) (6)
Treatment of Adenocarcinoma of the Endometrium at Memorial-James Ewing Hospitals, 1949-1965 (1976) (6)
Menstrual Dysfunction Following Use of Oral Contraceptives (1970) (6)
Chemotherapy of advanced ovarian epithelial carcinoma with melphalan and levamisole: a pilot study of the Gynecologic Oncology Group. (1981) (6)
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies (2004) (6)
Evaluating the acquisition of colposcopy skills in an obstetric-gynecologic residency program. (1985) (6)
Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum (a Gynecologic Oncology Group Study). (1987) (6)
Phase II study of Baker's antifol (triazinate, TZT, NSC-139,105) in advanced squamous cell carcinoma of cervix. (1982) (6)
Is hysterectomy a risk factor for vaginal cancer? (1987) (5)
Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. (1983) (5)
Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma. (1989) (5)
In vitro growth characteristics and chemosensitivities of endometrial cancer using a soft agar clonogenic assay (1987) (5)
Positive groin lymph nodes in vulvar cancer with superficial tumor penetration (1984) (4)
ICRF‐159 (Razoxane) in Patients with Advanced Nonsquamous Cell Carcinoma of the Cervix A Gynecologic Oncology Group Study (1986) (4)
Gynecologic problems in older women. (1998) (4)
Low-Dose Carbenicillin Prophylaxis for Vaginal and Abdominal Hysterectomy (1978) (4)
Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): The role of a new chemotherapy (CT) induced apoptosis assay. (2010) (4)
Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (A phase II trial of the gynecologic oncology group) (2004) (4)
Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study (1983) (4)
Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers (2014) (4)
Quality of Life Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: a Gynecologic Oncology Group Study (2011) (4)
Hexamethylmelamine as first‐line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group (1989) (4)
Cisplatin‐ based chemotherapy of epithelial ovarian cancer (1989) (3)
Phase II trial of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. (1987) (3)
Treatment of ovarian germ cell tumors with cisplatin + vinblastine + bleomycin: Longterm results of therapy (1984) (3)
A phase II trial of weekly one hour paclitaxel as second-line therapy for endometrial and cervical cancer. (2006) (3)
Endometrial carcinoma in-vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic (MICK) apoptosis assay: Implications for endometrial cancer treatment (2010) (3)
Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer. (1998) (3)
Evaluation of the abnormal Pap smear. (1977) (3)
Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group study (1984) (3)
Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms (1985) (3)
Treatment of Vaginal Intraepithelial Neoplasia With the Carbon Dioxide Laser (1983) (3)
Observations on bladder function following radical hysterectomy using carbon dioxide cystometry. (1978) (3)
Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study. (1986) (3)
Ineffectiveness of povidone-iodine irrigation of abdominal incisions. (1980) (3)
Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters: Interim Results of a Phase 2, Multicenter, Randomized, Double-Blind Study (NuCath). (2004) (3)
Incisional recurrence of carcinoma. (1982) (2)
Staging and current treatments for endometrial cancer. (1987) (2)
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma (2004) (2)
Leukemogenesis related to chemotherapy of ovarian carcinoma: a review with three new case reports. (1984) (2)
Morphine: immediate release vs. controlled release. (1989) (2)
Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study. (1984) (2)
Single agent weekly methotrexate (MTX) therapy in the treatment of nonmetastatic gestational trophoblastic disease (NMGTD) (1987) (2)
Randomized study of radiation therapy (Regimen I=Reg. I) versus pelvic node resection (Regimen II=Reg. II) for patients with invasive squamous cell carcinoma of the vulva having positive groin nodes (1985) (2)
Comparison of heparin and intermittent calf compression for prevention of pulmonary embolism (1983) (1)
Combined interferon alfa and doxorubicin in the treatment of advanced cervical cancer. (1991) (1)
Phase II trial of liposomal doxorubicinin disseminated endometrial carcinoma: A Gynecologic Oncology Group study (2005) (1)
Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary (2004) (1)
Normal and neoplastic tissue effects of high intensity intracavitary irradiation: cancer of the corpus uteri. (1974) (1)
Chemotherapy of advanced carcinoma of the cervix with cyclophosphamide and cisplatin. A pilot study of the gynecologic oncology group (1981) (1)
Assessment of Colposcopic Skills (1987) (1)
Concurrent chemotherapy and single high‐dose plus whole abdominopelvic radiation for persistent ovarian carcinoma (1990) (1)
Phase II trial of menogaril (NSC 269148) in chemotherapy-naive patients with advanced squamous carcinoma of the cervix (1992) (1)
Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay. (1993) (1)
An in vitro thymidine incorporation assay for human cancers: technical details revisited. (1992) (1)
A748 MULTICENTER, DOUBLE-BLIND, RANDOMIZED COMPARISON OF ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) VS. PLACEBO IN CANCER PATIENTS WITH BREAKTHROUGH PAIN (1997) (1)
Vincristine, cyclophosphamide, and adriamycin in advanced ovarian cancer (1978) (0)
Lethal peritonitis following internal small bowel herniation and infarction after use of a simplified stapler colostomy technique. (1980) (0)
Book ReviewPractical Gynecologic Surgery: Principles in Practice (1990) (0)
Proliferating Brenner tumor. (1977) (0)
Performance of a biomarker panel to identify malignancy within a pelvic mass population. (2009) (0)
Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Commentaries (1995) (0)
Carcinoma of the Cervix Complicated by a Soup Spoon (1978) (0)
Specificity and activity of autologous antibodies eluted from membrane fragments isolated from human ovarian epithelial neoplastic effusions (1985) (0)
[Vulvar cancer]. (1986) (0)
Dose intensity study of weekly intramuscular methotrexate (WIM) for nonmetastatic gestational trophoblastic disease (NGTD) (a Gynecologic Oncology Group (GOG) study) (1989) (0)
Commentary (Homesley/Muss): Role of Chemotherapy Dose Intensification in the Treatment of Advanced Ovarian Cancer (1995) (0)
Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study. (1983) (0)
Book Review Textbook of Gynecologic Oncology Edited by G.R.P. Blackledge, J.A. Jordan, and H.M. Shingleton. 504 pp., illustrated. Philadelphia, W.B. Saunders, 1991. $60. (1991) (0)
Screening for cervical cancer: 1982--an update. (1982) (0)
Combined Therapy in Uterine Cancer: Future Directions (2005) (0)
Phase II trial of ifosfamide and mesna in refractory epithelial ovarian carcinoma (1989) (0)
Is there a "best time" for postpartum vaginal hysterectomy? (1972) (0)
Malignant ovarian tumors simulating hydatidiform mole on ultrasound (1982) (0)
Book ReviewGynecologic Oncology (1986) (0)
Patient Characteristics and Outcomes for Locally Advanced Cervical Cancer in Minority and Underserved Populations in Eastern North Carolina (2007) (0)
Part 2 of 12 : Case Studies in Recurrent Gynecologic and Lung Cancer : Chemotherapeutic Innovations Watch Your (0)
Characteristics of Patients With Small-Volume Residual Ovarian Cancer Unresponsive to Cisplatin-Based Intraperitoneal Chemotherapy: Lessons Learned from a Gynecologic Oncology Group Phase II Trial of Interperitoneal Cisplatin and Recombinant α-Interferon (1992) (0)
Carcinoma of the endometrium : issues of the 1990s (1994) (0)
Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response (2012) (0)
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study. (1984) (0)
A phase I trial of recombinant leukocyte α2 interferon in patients with advanced malignancy (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Howard D. Homesley?

Howard D. Homesley is affiliated with the following schools: